source: msif.org
From the Departments of Neurology and Neuroscience (D.C., J.L., J.C., K.S., S.S.K., A.R.P., S.D.C.), Radiology (L.J.W.), and Preventive Medicine and Community Health (J.S.) of UMDNJ-New Jersey Medical School, Newark; and the Multiple Sclerosis Center at Holy Name Hospital (D.C., S.S.K., J.H.), Teaneck, NJ.
In this randomized trial the efficacy of IFNb-1b (Betaferon/Betaseron®) and glatiramer acetate (GA, Copaxone®) were compared. Seventy-five people with RRMS were included in the study. After a 2-year treatment period the authors found no differences between the 2 groups in terms of MRI activity (new lesions and enhancing lesions) and clinical activity (new relapses). Please return here to post comments - Thank You
============================================
0 comments:
Post a Comment